Icariin enhances cell survival in lipopolysaccharide-induced synoviocytes by suppressing ferroptosis via the Xc-/GPX4 axis

Abstract

The mechanism of action of synovitis, as the vital pathological process of rheumatoid arthritis and osteoarthritis, remains to be elucidated. The effects and the mechanism of icariin (ICA), which is a promising therapeutic agent in synovitis, was investigated in the present study. In addition, ferroptosis, a vital cell process involved in several diseases, was also studied in synovitis for the first time. Lipopolysaccharide (LPS)-induced synoviocytes served as a synovitis cell model. The cells were divided into control, LPS and experimental groups and were treated with different concentrations of ICA. Cell viability was determined by Cell Counting Kit-8 assay and cell death was determined by flow cytometry. The expression levels of proteins (GPX4, SLC7A11, SLC3A2L, TRF, Nrf2 and NCOA4) were measured by western blotting. Quantification of malondialdehyde (MDA), iron and glutathione peroxidase 4 (GPX4) activity levels were performed via using corresponding assay kits. Cell death was increased, and cell viability was decreased in LPS-induced synoviocytes. Furthermore, MDA levels and iron content were elevated and GPX levels was reduced in LPS-induced synoviocytes. Transferrin receptor protein 1 and nuclear receptor coactivator 4 were upregulated and proteins of the Xc-/GPX4 axis, as well as nuclear factor erythroid 2-related factor 2, were decreased by LPS treatment. All aforementioned LPS affects were alleviated by ICA via a concentration-dependent manner. ICA counteracted the effects of RSL3, a ferroptosis activator, on cell viability, lipid peroxidation, iron content and relative protein expression of ferroptosis in synoviocytes. ICA protects the cells from death in synoviocytes induced by LPS, via the inhibition of ferroptosis by activating the Xc-/GPX4 axis, which can be exploited as a new therapeutic strategy for synovitis.

Introduction

Rheumatoid arthritis is a chronic inflammatory disease caused by the dysregulation of the autoimmune system, which severely threatens the individual's health (1). Approximately 1% of the population suffers from rheumatoid arthritis worldwide, placing a heavy burden on economy and health (2). Chronic inflammation in rheumatoid arthritis leads to synovial hyperplasia and serious damage in the joints and cartilage (3). Rheumatoid arthritis is confirmed as a progressive disease and is also able to induce numerous implications on osteoporosis, myocarditis, neuropathy and pleurisy (4-6). Genetic and environmental factors are considered as the major contributors to rheumatoid arthritis (7,8). Furthermore, the exact mechanism of the pathogenesis and progression of rheumatoid arthritis remains unknown (9). The major characteristic of rheumatoid arthritis is synovitis (10). Normal synovium mainly consists of fibroblast-like synoviocytes and acts as a nutrient supplier for articular cartilage and protector of joint structures or adjacent tissues (10). The number of synovial cells are significantly increased in rheumatoid arthritis and are capable of causing destruction in the joint via the release of pro-inflammatory factors (11,12). In addition, synovitis is also involved in osteoarthritis. During osteoarthritis, stromal vascularization, fibrosis and hyperplasia occur in the synovium (13). Synovitis is closely associated with dysfunction and damage of the joint, as well as pain, and also contributes to the degeneration of cartilage in osteoarthritis (14). Therefore, it is important to find an effective therapeutic agent for synovitis and elucidate its mechanism, which will be beneficial for both the treatment of rheumatoid arthritis and osteoarthritis.

Icariin (ICA) as a bioactive monomer extracted from Epimedium in the Berberidaceae family, which exerts anticancer, antiaging, neuroprotective and anti-inflammation effects (15-18). ICA is confirmed as a promising agent for the treatment of rheumatoid arthritis and osteoarthritis in several previous studies. ICA was reported to inhibit osteoarthritis via suppressing pyroptosis mediated by NLRP3(19). ICA repressed the death and angiogenesis of chondrocytes in a rat osteoarthritis model via the modulation of the TDP-43 signaling pathway (20), enhanced chondrocyte viability via promoting anaerobic glycolysis and the expression of hypoxia-inducible factor-1α (21), exerted an immune-suppressive role in rheumatoid arthritis (22) and ameliorated rheumatoid arthritis in in a murine model of rheumatoid arthritis (23). However, the mechanism of ICA in rheumatoid arthritis and osteoarthritis is not fully elucidated, and clarifying the concrete mechanism is beneficial for developing more therapeutic drugs based on this compound.

Synovitis, as the crucial pathological process in rheumatoid arthritis and osteoarthritis, is a vital research topic. During synovitis, oxidative stress and lipid peroxidation are all involved and are confirmed as vital contributors to the pathological progress (24-26). Moreover, oxidative stress and lipid peroxidation are two major causes for ferroptosis, which is an iron-dependent, non-apoptotic form of cell death, characterized by the intracellular accumulation of reactive oxygen species. Thus, it is speculated that ferroptosis is a crucial process for injury in synovitis (27). Simultaneously, ICA has a regulatory role on iron metabolism (28). Therefore, the treatment effects of ICA may be related to the modulation of ferroptosis. In the present study, LPS-induced synovitis served as the cell model and the association between ICA and ferroptosis was investigated in the cell model of synovitis.

Materials and methods

Cell culture and treatment

Human synoviocytes (HUM-CELL-0060; Wuhan PriCells Biomedical Technology Co., Ltd.) were cultured in DMEM (Thermo Fisher Scientific, Inc.) supplemented with 1% streptomycin-penicillin, 2 mM L-glutamine and 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in an incubator with 5% CO₂ at 37˚C. Cells at >80% confluence were treated with LPS (1 µg/ml; Sigma-Aldrich; Merck KGaA) for 24 h to establish a synovitis cell model as previously described (29). The cells were treated with LPS for 24 h, followed by pretreatment with 2 (low), 5 (mid) or 10 µM (high) ICA for 24 h. Cells with no treatment served as the control group. Next, in order to further investigate the potential mechanism of action of ICA, RSL3 was used to induce ferroptosis in synoviocyte. We pre-treated synoviocyte with RSL3 (1 µM, cat. no. HY-100218A, MedChemExpress, China) for 8 h. After that, cells were incubated with ICA for 24 h and used for further experiments.

Measurement of cell death

Following LPS and ICA treatment, cells were digested by trypsin (0.25%) and resuspended in binding buffer. Subsequently, the cells were incubated with Annexin V-FITC for 15 min at 37˚C in the dark. Subsequently, propidium iodide was added into the cells for 2 min at 37˚C before measurement. Flow cytometry (BD FACSCanto II; BD Biosciences) was used for cell death measurement. The apoptotic cells were analyzed using a FlowJo™ v10.7 software (Becton-Dickinson & Company). The levels of cell death were calculated using the formula: Cell death ratio=Q1 + Q2 + Q3.

Quantification of malondialdehyde (MDA), iron and glutathione peroxidase 4 (GPX4) activity levels

The levels of MDA, iron and GPX4 activity were determined using their corresponding kits. MDA was detected via using the Lipid Peroxidation (MDA) Assay kit (cat. no. ab118970; Abcam), iron was determined by using the Iron Assay kit (cat. no. ab83366; Abcam) and GPX4 was detected using the GPX activity detection kit (cat. no. BC1195; Beijing Solarbio Science & Technology Co., Ltd.). All detection processes were performed according to the manufacturer's protocol.

Western blotting

The cells were harvested after treatment and, following lysis in NP40 buffer (Beijing Solarbio Science & Technology Co., Ltd.), the supernatant was centrifuged at 4˚C at 12,000 x g for 15 min for collecting the samples. The BCA protein Assay kit (cat. no. P0012S; Beyotime Institute of Biotechnology) was used to quantify protein samples. Subsequently, separation of the total protein was performed on 10% SDS-PAGE. Next, the proteins were transferred to polyvinyl difluoride membranes (Bio-Rad Laboratories, Inc.). Following blocking with 5% skim milk at room temperature for 1 h, the membranes were incubated with primary antibodies against GPX4 (1:10,000, cat. no. ab125066; Abcam), cystine/glutamate transporter (1:10,000, SLC7A11; cat. no. ab37185; Abcam), 4F2 cell-surface antigen heavy chain (1:1,000, SLC3A2L; cat. no. ab215952; Abcam), transferrin receptor protein (1:1,000, TFR; cat. no. ab84036; Abcam), nuclear factor erythroid 2-related factor 2 (1:500, Nrf2; cat. no. ab62352; Abcam), nuclear receptor coactivator 4 (1:100, NCOA4; cat. no. ab62495; Abcam) and GADPH (1:1,000, cat. no. ab8245; Abcam) overnight at 4˚C. Subsequently, HRP-conjugated secondary antibody (HRP goat anti-rabbit, 1:20,000, cat. no. ab97051; HRP goat anti-mouse, cat. no. ab205719, 1:10,000) was incubated with the membranes at room temperature for 2 h. ECL Plus Western Blotting Substrate (Pierce; Thermo Fisher Scientific, Inc.) was used to visualize protein bands, and ImageJ software (version 1.52v; National Institutes of Health) was used for quantification.

Cell Counting Kit-8 (CCK-8) assay

Cell viability was determined using a CCK-8 assay. The cells were cultured in 96-well plates at a density of 1x10⁵ cells/well. After treatment, CCK-8 reagent (10 µl; Beyotime Institute of Biotechnology) was added to the cells. After incubation for 2 h, the absorbance of cells at a wavelength of 450 nm was determined in the different study groups using a microplate reader (Omega Bio-Tek, Inc.).

Statistical analysis

Data were processed using SPSS 18.0 software (SPSS, Inc.) and GraphPad Prism 8.0 (GraphPad Software, Inc.) and shown as the mean ± SD. One-way ANOVA with Tukey's test was used for evaluating significant differences between groups. P<0.05 was considered to indicate a statistically significant difference.

Results

ICA attenuates cell death and increases cell viability in LPS-induced synoviocytes

In the LPS group, cell viability significantly decreased (Fig. 1A) and cell death significantly increased compared with the control group (Fig. 1B and C), suggesting that the synovitis cell model was successfully established. Simultaneously, LPS-induced cell death was decreased by ICA and LPS-induced cell viability was increased by ICA in a concentration-dependent manner, suggesting that ICA has protective effects in LPS-induced synoviocytes.

Figure 1.

The effects of ICA on cell viability and death. (A) Cell viability and (B and C) cell death in the different study groups. Experimental data were obtained from five independent experiments and shown as the mean ± standard deviation. ^***P<0.001 vs. control; ^#P<0.05, ^##P<0.01 and ^###P<0.001 vs. LPS; ^@P<0.05 vs. ICA-Low; ^&&P<0.01 vs. ICA-Mid. ICA, icariin; ICA-Low, 2 µM ICA; ICA-Mid, 5 µM ICA; ICA-High, 10 µM ICA; LPS, lipopolysaccharide.

ICA reduces MDA levels and iron content and increases GPX levels in a concentration-dependent manner in LPS-induced synoviocytes

Lipid peroxidation is a type of oxidative stress and is a vital process in rheumatoid arthritis and osteoarthritis (30,31). MDA, as the common biomarker of lipid peroxidation (32), was detected in the present study. There was a significant increase in MDA levels in the LPS group compared with the control (Fig. 2A), suggesting that lipid peroxidation levels are high in the synovitis cell model. MDA levels induced by LPS was reduced by MDA in a concentration-dependent manner, indicating that ICA has attenuative effects on lipid peroxidation in LPS-induced synoviocytes. Iron was confirmed as the stimulator of oxidative stress and iron overload (33,34). In the present study, the iron content was significantly increased in the LPS group compared with the control group. The iron content induced by LPS was reduced by ICA in a concentration-dependent manner (Fig. 2B), demonstrating that ICA could attenuate the iron deposit in LPS-induced synoviocytes. GPX, an antioxidant enzyme (35), was also detected in the present study. GPX levels were significantly reduced by LPS compared with the control group. The levels of GPX induced by LPS was further increased by ICA in a concentration-dependent manner. These results suggested that ICA exerted antioxidant effects by reducing MDA levels and iron content and increasing GPX levels in LPS-induced synoviocytes.

Figure 2.

Effects of ICA on the levels of MDA, iron content and GPX. The levels of (A) MDA, (B) iron content and (C) GPX in the study groups. Experimental data were obtained from five independent experiments and shown as the mean ± standard deviation. ^@@P<0.01 and ^@@@P<0.001 vs. ICA-Low; ^***P<0.001 vs. control; ^#P<0.05, ^##P<0.01 and ^###P<0.001 vs. LPS. ICA, icariin; ICA-Low, 2 µM ICA; ICA-Mid, 5 µM ICA; ICA-High, 10 µM ICA; LPS, lipopolysaccharide; MDA, malondialdehyde; GPX, glutathione peroxidase.

ICA regulates the relative expressions level of ferroptosis proteins in LPS-induced synoviocytes

Lipid peroxidation and iron metabolism disorder, which are the major inducers of ferroptosis (36), both occurred in LPS-induced synoviocytes. Considering the attenuative effects of ICA on iron content and lipid peroxidation levels, it was speculated that there may be an association between ferroptosis and ICA. Xc-/GPX4, which is capable of suppressing lipid peroxidation, is a vital pathway for the inhibition of ferroptosis (37). In the current study, GPX4, SLC7A11 and SLC3A2L expression were all significantly decreased by LPS compared with controls, and this effect was further inhibited by ICA (Fig. 3), confirming that ICA inhibited ferroptosis via the activation of Xc-/GPX4. Pathways that are associated with iron metabolism were also investigated in the present study. TFR1, a vital importer for iron transport into the cells (38), was significantly upregulated by LPS compared with the control group, which is consistent with the high levels of iron content in the LPS group. The TFR1 levels induced by LPS was decreased by ICA in a concentration-dependent manner, suggesting that inhibition of TFR1 is one of the avenues for the inhibitory effect of ICA on ferroptosis in LPS-induced synoviocytes. Nrf2 acts as a crucial factor for inhibition of ferroptosis (39), which was significantly reduced by LPS and further elevated by ICA in a concentration-dependent manner in LPS-induced cells. NCOA4 acts as mediator of ferritinophagy, resulting in iron accumulation and ferroptosis (40). As shown by the present data, NCOA4 levels were significantly upregulated in the LPS group compared with controls. Following ICA treatment, the NCOA4 levels induced by LPS gradually decreased upon increasing concentrations of ICA. Collectively, ICA inhibited ferroptosis via the activation of Xc-/GPX4 and Nrf2, and inhibition of TFR1 and NCOA4.

Figure 3.

Effects of ICA on the levels of ferroptosis-associated proteins. The levels of proteins associated with ferroptosis in the study groups. The representative blot of five independent experiments with similar results are expressed as the mean ± standard deviation. ^***P<0.001 vs. control; ^**P<0.01 vs. control; ^#P<0.05, ^##P<0.01 and ^###P<0.001 vs. LPS. ICA, icariin; ICA-Low, 2 µM ICA; ICA-Mid, 5 µM ICA; ICA-High, 10 µM ICA; LPS, lipopolysaccharide; SLC7A111, cystine/glutamate transporter; GPX, glutathione peroxidase; SLC3A2L, 4F2 cell-surface antigen heavy chain; TFR1, transferrin receptor protein 1; Nrf2, nuclear factor erythroid 2-related factor 2; NCOA4, nuclear receptor coactivator 4.

ICA attenuates cell death via inhibition of ferroptosis by activating the Xc-/GPX4 axis

In order to further investigate the underlying mechanism, the effects of ICA after blockage of Xc-/GPX4 axis with RSL3 was further assessed. RSL3 is known to be a type of ferroptosis activator (41). As shown by the data, the cell viability was significantly reduced and cell death was increased in the RSL3 group compared with the controls (Fig. 4A-C), confirming that marked ferroptotic cell death was observed after RSL3 induction. Iron and MDA content significantly increased and GPX levels significantly decreased in the RSL3 group compared with the ICA + RSL3 group (Fig. 5A-C). Thus, the effects of RSL on lipid peroxidation and iron content were counteracted by ICA and the effects of ICA in cells were achieved via activation of the Xc-/GPX4 axis. The expression of ferroptosis-associated proteins was also investigated. Compared with the ICA + RSL3 group, Xc-/GPX4-associated proteins (SLC7A11, GPX4 and SLC3A2L) and Nrf2 expression were significantly reduced by RSL3, demonstrating that Xc-/GPX4 and Nrf2 were activated by ICA (Fig. 6). Following the blockage of the Xc-/GPX4 axis, there was almost no difference in the levels of NCOA4 and TFR1 between the ICA + RSL3 group and RSL3 group, suggesting that NCOA4 and TFR1 were not the major players in the mechanism of ICA. All these results support that the Xc-/GPX4 axis is involved in the effects of ICA via the modulation of ferroptosis.

Figure 4.

Effects of ICA on cell death and viability following inhibition of the Xc-/glutathione peroxidase 4 axis. (A) cell viability and (B and C) cell death in the different study groups. Experimental data were obtained from five independent experiments and shown as the mean ± standard deviation. ^*P<0.01 and ^***P<0.001 vs. control; ^#P<0.05 and ^##P<0.01 vs. RSL3. ICA, icariin.

Figure 5.

Effects of ICA on the levels of MDA, iron content and GPX following inhibition of the Xc-/GPX4 axis. The levels of (A) MDA, (B) iron content and (C) GPX in the study groups. Bar graphs were drawn from five independent experiments. Results were expressed as the mean ± standard deviation. ^*P<0.05 and ^***P<0.001 vs. control; ^##P<0.01 and ^###P<0.001 vs. RSL3. ICA, icariin; MDA, malondialdehyde; GPX, glutathione peroxidase.

Figure 6.

Effects of ICA on ferroptosis-associated protein expression following inhibition of the Xc-/GPX4 axis. The expression levels of ferroptosis-associated proteins in the study groups. The protein levels been standardized against GAPDH expression. Values are expressed as the mean ± standard deviation. ^**P<0.01 and ^***P<0.001 vs. control; ^#P<0.05, ^##P<0.01 and ^###P<0.001 vs. RSL3. ICA, icariin; SLC7A111, cystine/glutamate transporter; GPX, glutathione peroxidase; SLC3A2L, 4F2 cell-surface antigen heavy chain; TFR1, transferrin receptor protein 1; Nrf2, nuclear factor erythroid 2-related factor 2; NCOA4, nuclear receptor coactivator 4.

Discussion

ICA has been demonstrated to serve a vital role in both rheumatoid arthritis and osteoarthritis and reported to act as a regulator of gene expression and cellular functions in the synoviocytes of osteoarthritis (19,42). ICA reduces the number of Th17 cells, resulting in repression of the generation of IL-1 in rheumatoid arthritis (23). Synovitis is the vital pathological process for arthritis and osteoarthritis (13). The mechanism and effects of ICA in synovitis is still not fully elaborated. In the present study, it was found that ICA protected synoviocytes from death via the modulation of ferroptosis.

Ferroptosis was confirmed to be involved in several pathological processes. Ferroptosis is confirmed as the novel mechanism of anticancer agents, such as non-small cell lung cancer and breast cancer (43). Edaravone functions in amyotrophic lateral sclerosis via the inhibition of ferroptosis (44). Ferroptosis, which contributes to the progress of ulcerative colitis, is a promising treatment target for ulcerative colitis (45). However, whether ferroptosis is involved in osteoarthritis or rheumatoid arthritis is still unknown. Lipid peroxidation and abnormal iron metabolism, as critical stimulators for ferroptosis, are involved in osteoarthritis and rheumatoid arthritis (46-50). Thus, it was postulated that ferroptosis may be also be involved in synovitis, which is the vital process of osteoarthritis and rheumatoid.

As ferroptosis is a form of inducing cell death, the cell viability was evaluated in the present study. It was found that the cell viability was significantly reduced in the cell model of LPS-induced synoviocytes, which is further confirmed by cell death observed in the LPS group. The cell death induced by LPS was significantly reduced by ICA at a high concentration. The lipid peroxidation and iron content levels were detected to determine whether the cell death in the LPS group was induced by ferroptosis. MDA, as a common indicator of lipid peroxidation, is increased in synoviocytes with osteoarthritis and rheumatoid arthritis (51,52). Simultaneously, GPX, an anti-oxidant agent, is decreased in osteoarthritis and rheumatoid arthritis (53,54). Consistent with previous studies, MDA levels were increased and GPX levels were decreased in the LPS group. Furthermore, it was found that ICA reversed the effects on MDA and GPX levels induced by LPS in a concentration-dependent manner. Abnormal iron metabolism is another contributor of ferroptosis and iron deposits are found in osteoarthritis and rheumatoid arthritis (50,55,56). In accordance with previous studies, it was found that the iron content was increased in the LPS group. In addition, ICA reduced the iron content induced by LPS. Collectively, the data demonstrated that ferroptosis may be involved in synovitis and ICA exerted inhibitory effects on ferroptosis.

To further confirm the results observed, ferroptosis-associated proteins were detected in the present study. The Xc-/GPX4 axisregulated lipid ROS levels and its inhibition contributed to ferroptosis (57). In the present study, the levels of GPX4, SLC7A11 and SLC3A2L were decreased in the LPS group and this effect was inhibited by ICA, suggesting that ferroptosis was involved in synovitis and ICA inhibited ferroptosis. TFR1 and NCOA4, as contributors of ferroptosis were increased by LPS, and Nrf2 was reduced by LPS, confirming that ferroptosis was involved in synovitis. Furthermore, the effects of LPS on the levels of TFR1, NCOA4 and Nrf2 were all alleviated by ICA via a concentration-dependent manner, further supporting that ICA has suppressive effects on ferroptosis.

RSL3, a GPX4 inhibitor (58), was used to investigate whether the Xc-/GPX4 axis was the main avenue for the inhibitory effects of ICA on ferroptosis. As expected, cell viability was decreased and cell death was increased by RSL3, suggesting that following inhibition of the Xc-/GPX4 axis, ferroptosis was enhanced. Lipid peroxidation and iron content were elevated by RSL3. Moreover, the aforementioned effects of RSL3 were reversed by ICA, confirming that ICA exerted inhibitory effects on ferroptosis via activation of the Xc-/GPX4 axis. GPX4, SLC7A11 and SLC3A2L were all reduced by RSL3 and this effect was partly reversed by ICA, strongly supporting that the protective effects of ICA on cell viability was mediated via activation of the Xc-/GPX4 axis, which protects against ferroptosis. ICA has no effects on the levels of TFR1, NCOA4 and SLC3A2L induced by RSL3, indicating that ICA exerted anti-ferroptosis mainly depending on SLC7A11-/GPX4 axis. Thus, the results confirm that the Xc-/GPX4 axis is a mediator for the protective effects of ICA in synovitis.

To the best of our knowledge, the present study first identified that ferroptosis was involved in synovitis and ICA exerted protective effects via inhibition of ferroptosis and by the activation of the Xc-/GPX4 axis in synovitis, providing a new strategy for the treatment of synovitis. However, the ferroptosis regulation of ICA via Xc-/GPX4 axis in osteoarthritis needs to be further confirmed through in vivo study. Determining how other ferroptosis activator or inhibitors affect ferroptosis of osteoarthritis would be helpful to further understand the mechanism of ICA in ferroptosis.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

HL and RZ conceived and designed the study, collected, analysed and interpreted the data, and revised the manuscript. HL wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.